Clinical Trials
Recursion Doses First Patient in Phase 2 Trial of REC-3964, a Novel Non-Antibiotic Treatment for Recurrent C. difficile Infection
REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a uni...
October 23, 2024 | News
Minghui Pharmaceutical Reports Positive Results from Phase Ib/II Trial of MHB018A in Thyroid Eye Disease Patients
Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, ann...
October 23, 2024 | News
LaNova Medicines Initiates Phase 1 Trial of Anti-PD-1/VEGF BsAb LM-299 in China for Advanced Solid Tumors
Phase 1 trial of LM-299, an anti-PD-1/VEGF BsAb, initiated in China for advanced solid tumors following promising preclinical results demonstra...
October 21, 2024 | News
CSL Vifor and Travere Therapeutics Secure Swissmedic Approval for FILSPARI in Treatment of IgA Nephropathy
CSL Vifor and Travere Therapeutics, announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults w...
October 18, 2024 | News
Antengene’s XPOVIO® Gains Third Approval in South Korea for Multiple Myeloma Treatment
This approval for XPOVIO® for the treatment of patients with multiple myeloma (MM) marks the third approved indication of the drug in South...
October 18, 2024 | News
Alphamab Oncology and CSPC Pharmaceutical's Phase III Trial of KN026 for HER2-Positive Breast Cancer Receives Approval from NMPA
Alphamab Oncology (stock code: 9966 HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK) jointly announced that an applicat...
October 17, 2024 | News
Innovent Biologics' Picankibart Achieves Primary Endpoint in Phase 2 Clinical Study for Ulcerative Colitis
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
October 17, 2024 | News
TenNor Therapeutics Secures Over 300 Million RMB in Series E Funding to Advance Novel Antibiotics for Drug-Resistant Infections
TenNor Therapeutics, a clinical stage company dedicated to developing new therapies to address unmet needs in infectious diseases, announced today the init...
October 17, 2024 | News
SONIRE Therapeutics Secures FDA Breakthrough Device Designation for Advanced HIFU Therapy in Pancreatic Cancer
SONIRE Therapeutics Inc. (hereinafter referred to as "SONIRE"), based in Tokyo, Japan, announces that its self-developed next-generation HIFU (Hi...
October 17, 2024 | News
Endogenex Achieves Key Clinical Milestone with First Patient Enrolled in ReCET™ Study for Type 2 Diabetes Treatment
Achieving a Significant Clinical Milestone in Assessing the ReCET™ System as a Groundbreaking Treatment for Type 2 Diabetes Endogenex, Inc., a clini...
October 16, 2024 | News
PharmAbcine Receives Safety Approval for 4mg Dose in Phase 1 Trial of PMC-403, Paving the Way for Multiple Ascending Dose Study
Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC-403, preparing for multiple ascending dose 4 mg cohort. ...
October 15, 2024 | News
Australian Clarity Pharmaceuticals Receives Positive FDA Feedback for Pivotal Phase III Trial of 64Cu-SAR-bisPSMA in Prostate Cancer
United States Food and Drug Administration (U.S. FDA) provided positive feedback on a pivotal Phase III trial for 64Cu-SAR-bisPSMA diagnostic in pro...
October 15, 2024 | News
Dizal Receives Fourth Breakthrough Therapy Designation for Sunvozertinib in EGFR Exon20ins NSCLC
Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins Dizal (SSE:688192), a biopharmaceutical company committed to d...
October 14, 2024 | News
Akeso Biopharma Secures $250 Million in Share Placement to Accelerate Global Clinical Trials
Expediting International Clinical Trials for Pivotal Products Key Participants Include International Long-Term and Healthcare Funds Akeso Biopharma annou...
October 14, 2024 | News
Most Read
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
